The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Phase 1

Completed

• Conditions: Heart Failure
• Interventions: Drug: Glucagon-Like Peptide 1

• Registration Number: NCT02129179
• Lead Sponsor: Papworth Hospital NHS Foundation Trust

Brief Summary

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-30
• Study First Submitted QC: 2014-05-01
• Study First Posted: 2014-05-02
• Study Start: 2014-06
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Status Verified: 2018-04
• Last Update Submitted: 2018-04-03
• Last Update Posted: 2018-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Age over 18
• Able to give informed consent
• On the waiting list for heart transplant
• Left Ventricular Dysfunction awaiting catheterisation

Exclusion Criteria

• Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin
• Women of child bearing age and breast feeding women
• Cardiac pacemaker or other implanted metallic device
• Unable to give informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
GLP-1	Glucagon-Like Peptide 1	-

Primary Outcome Measures

Name	Time	Method
Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1	30 minutes

Trial Locations

Locations (1)

Papworth Hospital NHS Foundation Trust; 🇬🇧 Papworth Everard, United Kingdom